ULIPRISTAL ACETATE for adenomyosis
Ulipristal acetate is a progesterone receptor modulator acting on the progesterone receptor and is a Phase 2 clinical candidate for adenomyosis per Open Targets.
Hypothesized mechanism
As a selective progesterone receptor modulator, ulipristal acetate acts on the progesterone receptor to modulate progesterone signaling in adenomyotic endometrial/myometrial tissue.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 3.8 of 10 overall, a emerging reading, from a pathway rated emerging in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Female representation not stated — applicability to women uncertain (flagged for full text). (band F4, ×0.75).
Corroboration
Only a single source (Open Targets) provides one line of evidence: a database annotation that ULIPRISTAL ACETATE is a progesterone receptor modulator clinical candidate for adenomyosis. No independent mechanistic lines converge to support the claim.
Rigor
The evidence is a clinical-stage annotation (PHASE_2 candidate) rather than in-vitro data, which is human-relevant, but it is a bare database listing with no actual study results, models, or outcomes reported.
Specificity
The mechanism is stated as 'Progesterone receptor modulator on target progesterone receptor,' which names a defined target. However, selective progesterone receptor modulators have mixed agonist/antagonist activity and the annotation provides no detail on selectivity of action.
Plausibility
Adenomyosis is a progesterone/estrogen-dependent uterine disorder, so a progesterone receptor modulator acting on the progesterone receptor has a strong target-phenotype fit, consistent with its PHASE_2 clinical candidate status for this condition.
Consistency
With only one positive claim from a single source, there are no conflicting signals, but there is also no convergence of multiple mechanistic signals to assess consistency meaningfully.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Per Open Targets (retrieved 2026-06-16), ULIPRISTAL ACETATE (a Small molecule) is a clinical candidate for adenomyosis (maximum clinical stage PHASE_2); its mechanism of action is Progesterone receptor modulator on target progesterone receptor. Open Targets · mechanistic ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →